{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:18:04Z","timestamp":1777598284112,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.arbres.2016.12.011","type":"journal-article","created":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T00:45:54Z","timestamp":1489279554000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Normativa sobre el tratamiento farmacol\u00f3gico de la fibrosis pulmonar idiop\u00e1tica"],"prefix":"10.1016","volume":"53","author":[{"given":"Antoni","family":"Xaubet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Molina-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrella","family":"Fern\u00e1ndez-Fabrellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Rodr\u00edguez-Portal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2016.12.011_bib0235","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.arbres.2013.03.011","article-title":"Normativa sobre el diagn\u00f3stico y tratamiento de la fibrosis pulmonar idiop\u00e1tica","volume":"49","author":"Xaubet","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2016.12.011_bib0240","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0245","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0250","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of N-acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Martinez","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0255","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0260","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0265","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"17","author":"Sch\u00fcnemann","year":"2008","journal-title":"Br Med J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0270","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomized trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2016.12.011_bib0275","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0280","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0285","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0290","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12325-014-0112-1","article-title":"Pirfenidone in idiopathic pulmonary fibrosis: Expert panel discussion on the management of drug-related adverse events","volume":"31","author":"Costabel","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.arbres.2016.12.011_bib0295","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1183\/09059180.00011514","article-title":"Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis","volume":"24","author":"Cottin","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2016.12.011_bib0300","doi-asserted-by":"publisher","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: Integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Respir Res."},{"key":"10.1016\/j.arbres.2016.12.011_bib0305","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0310","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0315","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0320","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","author":"Kolb","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2016.12.011_bib0325","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000436980","article-title":"New treatments for idiopathic pulmonary fibrosis: \u2018Die another day\u2019 if diagnosed early?","volume":"90","author":"Antoniou","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.arbres.2016.12.011_bib0330","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/MCP.0000000000000190","article-title":"Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis","volume":"21","author":"King","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0335","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12890-016-0308-z","article-title":"Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: A case series","volume":"16","author":"Delanote","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0340","first-page":"CD002880","article-title":"Corticosteroids for idiopathic pulmonary fibrosis","volume":"3","author":"Richeldi","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2016.12.011_bib0345","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2016.12.011_bib0350","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0355","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: The future of management for idiopathic pulmonary fibrosis","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"Suppl 1","key":"10.1016\/j.arbres.2016.12.011_bib0360","first-page":"28","article-title":"Challenges in IPF diagnosis, current management and future perspectives","volume":"32","author":"Wells","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.arbres.2016.12.011_bib0365","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/resp.12477","article-title":"Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: A case-control study","volume":"20","author":"Sakamoto","year":"2015","journal-title":"Respirology"},{"key":"10.1016\/j.arbres.2016.12.011_bib0370","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1183\/09059180.00011414","article-title":"The changing treatment landscape in idiopathic pulmonary fibrosis","volume":"24","author":"Costabel","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2016.12.011_bib0375","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0380","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1378\/chest.129.3.794","article-title":"Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: A case series","volume":"129","author":"Raghu","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2016.12.011_bib0385","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0390","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid therapy and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomized controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0395","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: A pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0400","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1183\/13993003.00488-2016","article-title":"Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single center","volume":"48","author":"Raghu","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0405","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09059180.00000813","article-title":"The impact of emphysema in pulmonary fibrosis","volume":"22","author":"Cottin","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2016.12.011_bib0410","first-page":"767","article-title":"Combined pulmonary fibrosis and emphysema (CPFE): An entity different from emphysema or pulmonary fibrosis alone","volume":"7","author":"Huijin","year":"2015","journal-title":"J Thorac Dis"},{"issue":"Suppl 1","key":"10.1016\/j.arbres.2016.12.011_bib0415","first-page":"17","article-title":"IPF, comorbidities and management implications","volume":"32","author":"Vancheri","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.arbres.2016.12.011_bib0420","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1378\/chest.12-2403","article-title":"Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis","volume":"144","author":"Ryerson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2016.12.011_bib0425","first-page":"8617","article-title":"Clinical efficacy and safety of ICS\/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema","volume":"8","author":"Dong","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0430","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0435","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arbres.2016.12.011_bib0440","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2016.12.011_bib0445","first-page":"499","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: A review of current and novel pharmacotherapies","volume":"7","author":"Juarez","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.arbres.2016.12.011_bib0450","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: Incidence risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0455","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1183\/13993003.00419-2015","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: Shifting the paradigm","volume":"46","author":"Ryerson","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2016.12.011_bib0460","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary ibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"updated-by":[{"DOI":"10.1016\/j.arbres.2017.06.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000}}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289617300212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289617300212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T16:21:02Z","timestamp":1535991662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289617300212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0300289617300212"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2016.12.011","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.arbres.2017.06.010","asserted-by":"object"}]},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normativa sobre el tratamiento farmacol\u00f3gico de la fibrosis pulmonar idiop\u00e1tica","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2016.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}